GlassScriptPhysician profile
Ritu Aggarwal
NPI 1336277060
$6,836.84
in general payments reported to CMS, 2019-2025
36 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.97 · 2020: $130 · 2021: $1,578 · 2022: $879 · 2023: $1,331 · 2024: $1,290 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,253.47 | 2021 | |
| Abbvie INC. | $1,066.60 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $640.56 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $529.86 | 2023-2025 | |
| Lilly USA, LLC | $352.51 | 2021-2025 | Mounjaro, Emgality, Zepbound |
| Corium, LLC | $329.95 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $287.63 | 2022-2025 | Rexulti |
| Abbott Laboratories | $241.69 | 2023-2024 | Proclaim, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $221.54 | 2020-2025 | Trelegy Ellipta, Shingrix, Penmenvy |
| Amgen INC. | $215.03 | 2020-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $184.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $149.73 | 2022-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $149.05 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $110.44 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $85.38 | 2022-2025 | Veozah |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.